Email ID
Password
Scrip   
Doubts cast over GSK's $720 million sirtuin gamble
25 January 2010
Asher Mullard

An increasing body of evidence is suggesting that GlaxoSmithKline's portfolio of sirtuin 1 (SIRT1) activators, which it gained through its $720 million acquisition of Sirtris, do not do what they are supposed to.

"Any phenotype that you see with these compounds is not due to direct activation...



Please Login to read the full article.
JOB OF THE WEEK Promote your vacancy here
© 2010 Informa plc. All rights reserved.
This site is owned and operated by Informa plc ("Informa") whose registered office is Mortimer House, 37-41 Mortimer Street, London, W1T 3JH. Registered in England and Wales. Number 3099067. UK VAT Group: GB 365 4626 36